共 50 条
- [21] Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancerINVESTIGATIONAL NEW DRUGS, 2009, 27 (03) : 253 - 261Michael, MichaelGibbs, PeterSmith, RobertGodwood, AlexOliver, StuartTebbutt, Niall
- [22] Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancerInvestigational New Drugs, 2009, 27 : 253 - 261Michael MichaelPeter GibbsRobert SmithAlex GodwoodStuart OliverNiall Tebbutt
- [23] A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]ANNALS OF ONCOLOGY, 2021, 32 : S904 - S904Haydon, A. M.Alamgeer, M.Brungs, D.Collichio, F.Khushalani, N. I.Colevas, A. D.Rischin, D.Kudchadkar, R.Chai-Ho, W.Daniels, G.Lutzky, J.Lee, J. H.Bowyer, S.Migden, M. R.Sheladia, P.Bommareddy, P. K.He, S.Andreu-Vieyra, C.Fury, M. G.Hill, A.
- [24] Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II TrialCLINICAL CANCER RESEARCH, 2021, 27 (04) : 1003 - 1011Xu, JianmingShen, JieGu, ShanzhiZhang, YunWu, LihuaWu, JianShao, GuoliangZhang, YanqiaoXu, LiYin, TaoLiu, JingfengRen, ZhenggangXiong, JianpingMao, XianhaiZhang, LingYang, JiayinLi, LequnChen, XiaomingWang, ZhimingGu, KangshengChen, XiPan, ZhanyuMa, KuanshengZhou, XinminYu, ZujiangLi, EnxiaoYin, GuowenZhang, XiaoWang, ShuniWang, Quanren
- [25] BIODISTRIBUTION AND SHEDDING ANALYSIS FOLLOWING TREATMENT WITH RP1 ONCOLYTIC IMMUNOTHERAPY IN THE SKIN CANCER PATIENTS FROM THE IGNYTE CLINICAL TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A643 - A643Milhem, MohammedVanderWalde, AriBowles, TawnyaSacco, JosephOlsson-Brown, AnnaNiu, JiaxinTsai, KatyChesney, JasonChmielowski, BartoszSamson, AdelRhodes, TerenceIn, GinoPavlick, AnnaWise-Draper, TrishaSanmamed, MiguelKalbasi, AlirezaLove, ColinClack, AaronHou, JeannieBommareddy, PraveenCoffin, RobertMiddleton, MarkHarrington, Kevin
- [26] Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation.CANCER RESEARCH, 2021, 81 (13)Harrington, Kevin J.Aroldi, FrancescaSacco, Joseph J.Milhem, Mohammed M.Curti, Brendan D.Vanderwalde, Ari M.Baum, ScottSamson, AdelPavlick, Anna C.Chesney, Jason A.Niu, JiaxinRhodes, Terence D.Bowles, Tawnya L.Conry, RobertOlsson-Brown, AnnaLaux, Douglas E.Nenclares, PabloMenezes, LavitaDeterding, AlexRoulstone, VictoriaKyula, JoanThomas, SuzanneBommareddy, Praveen K.Samakoglu, SeldaPirzkall, AndreaCoffin, Robert S.Middleton, Mark R.
- [27] Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)CANCER RESEARCH, 2024, 84 (07)Migden, Michael R.Chai-Ho, WanxingDaniels, Gregory A.Medina, TheresaWise-Draper, Trisha M.Kheterpal, MeenalTang, Jennifer C.Ibrahim, Sherrif F.Bolotin, DianaVerschraegen, ClaireZeitouni, Nathalie C.Tsai, Katy K.Donthireddy, LaxminarasimhaBommareddy, Praveen K.Hou, Jeannie W.Hong, WalterDavar, Diwakar
- [28] Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2011, 12 (11): : 1032 - 1044Ducreux, MichelMalka, DavidMendiboure, JeanEtienne, Pierre-LucTexereau, PatrickAuby, DominiqueRougier, PhilippeGasmi, MohamedCastaing, MarineAbbas, MoncefMichel, PierreGargot, DanyAzzedine, AhmedLombard-Bohas, CatherineGeoffroy, PatrickDenis, BernardPignon, Jean-PierreBedenne, LaurentBouche, Olivier
- [29] AN OPEN-LABEL, MULTICENTER, PHASE 1/2 CLINICAL TRIAL OF RP1, AN ENHANCED POTENCY ONCOLYTIC HSV, COMBINED WITH NIVOLUMAB: UPDATED RESULTS FROM THE SKIN CANCER COHORTSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A257 - A257Middleton, MarkAroldi, FrancescaSacco, JosephMilhem, MohammedCurti, BrendanVanderWalde, AriBaum, ScottSamson, AdelPavlick, AnnaChesney, JasonNiu, JiaxinRhodes, TerenceBowles, TawnyaConry, RobertOlsson-Brown, AnnaLaux, Douglas EarlKaufman, HowardBommareddy, PraveenDeterding, AlexSamakoglu, SeldaCoffin, RobertHarrington, Kevin
- [30] Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Sacco, Joseph J.Harrington, Kevin JosephOlsson-Brown, AnnaChan, Tze Y.Nenclares, PabloLeslie, IslaBommareddy, PraveenKalbasi, AlirezaXie, BenMishal, MoranCohan, David MichaelSkolariki, AglaiaMiddleton, Mark R.